News|Videos|November 14, 2023

LIBRETTO-431: 1L Selpercatinib in RET Fusion–Positive Advanced NSCLC

Alexander Spira, MD, PhD, FACP, joins the Oncology Brothers in reviewing data from LIBRETTO-431 and frontline selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer.


Latest CME